Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 450 full-time employees. The company went IPO on 2017-12-07. The firm is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The firm's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
최신 재무제표(Form-10K)에 따르면, Quanterix Corp의 총 자산은 $0이며, 순손실입니다.
QTRX의 주요 재무 비율은 무엇인가요?
Quanterix Corp의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Quanterix Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Quanterix Corp 주요 수익원은 Ultra-sensitive Digital Immunoassay Platform이며, 최신 수익 발표에서 수익은 122,368,000입니다. 지역별로는 North America이 Quanterix Corp의 주요 시장이며, 수익은 76,512,000입니다.